Negative Myeloproliferative
TET2 Mutations in Ph Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings
... High-throughput DNA sequence analysis was used to screen for TET2 mutations in peripheral blood derived DNA from 97 patients with BCR-ABL-negative-myeloproliferative neoplasms (MPNs). Overall six mutations ...
6
Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
... Philadelphia-negative myeloproliferative neoplasms (MPNs) and respec- tive associations of anxiety and depression with demographic and lifestyle factors, comorbidity burden, duration of MPN disease, ...
11
Clinical Profile of Philadelphia Negative Myeloproliferative Neoplasms in India.
... Polycythemia vera is a chronic myeloproliferative neoplasm characterized by increased red blood cell production independent of the mechanisms that normally regulate erythropoiesis. The reported annual incidence of ...
87
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
... myeloproliferative neoplasms (MPNs). We performed high resolution melting analysis and Sanger sequencing together with T-A cloning to elucidate the unique mutation profile of these genes, in Chinese patients with ...
10
Prognostic significance of <em>ASXL1</em>, <em>JAK2V617F</em> mutations and <em>JAK2V617F</em> allele burden in Philadelphia-negative myeloproliferative neoplasms
... In our study, the frequency of combined JAK2V617F and ASXL1 mutations was significantly higher in PMF patients than in ET patients (18.2% and 5.6%, respectively). In PMF patients, no correlations were seen between HCT ...
19
Methylation of miR 34a, miR 34b/c, miR 124 1 and miR 203 in Ph negative myeloproliferative neoplasms
... as negative control, while enzymatically methylated control DNA (CpGenome Universal Methylated DNA, Chemicon) was used as positive control in all the experi- ...
10
MPL W515 L/K mutations in myeloproliferative neoplasms
... thrombocythemia (ET), and primary myelofibrosis (PMF). This classification is based on the presence of Philadelphia (Ph) chromosome (BCR/ABL1). CML is BCR/ABL1-positive while PV, ET, and PMF are negative. JAK2 p. ...
7
Original Article Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients
... In 2005, Janus kinase JAK2 mutation was dis- covered in some myeloproliferative disorders. The discovery of this mutation was represented a great progress in the understanding of BCR- ABL negative ...
5
Targeted therapies for myeloproliferative neoplasms
... BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment ...
8
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
... Abstract: Myelofibrosis (MF) is a rare chronic BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homologue 1)-negative myeloproliferative neoplasm character- ized by progressive ...
13
Frequency of L1721W Polymorphism in TET2 Gene Among a Cohort of Sudanese Patients with Myeloproliferative Disorders: Possible Roles in Pathogenicity and Leukemic Transformation
... (Mean±SD: 52.1±9.3); eight per cent (4/50, 8%) were less than 40 years of age. Two thirds (33/50, 66%) were within the age group 41 to 60 years of age. A quarter (13/50, 26%) were above 61 years of age (Table 1). ...
5
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
... occurred in four patients. Additional patients displayed par- tial responses, with either molecular remission or reversal in marrow fibrosis, but not both. Improvement in cytopenias and leukocytosis was also demonstrated ...
14
Conditional expression of oncogenic K ras from its endogenous promoter induces a myeloproliferative disease
... malignant myeloproliferative syn- dromes, which include monosomy 7 syndrome and juvenile myelomonocytic leukemia (JMML) ...a myeloproliferative syndrome resembling human JMML ...JMML-like ...
12
Hypereosinophilic syndromes
... Interferon-α has also been used successfully for manage- ment of HES [31]. Although highly variable dosing regi- mens have been used, it appears that doses of 1–2 million units/d are often sufficient to control ...
12
Pulmonary hypertension in patients with chronic myeloproliferative disorders
... primary myeloproliferative disorder in 78% of cases with apparent idiopathic Budd – Chiari syndrome and in about half of patients with portal, splenic and/or mesenteric venous thrombosis [32, ...
11
The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia
... MPN: myeloproliferative neoplasms; PV: polycythaemia vera; ET: essential thrombocythaemia; PMF: primary myelofibrosis; EPO: erythropoietin; JAK 2: Janus kinase 2 domain; MPN-U: myeloproliferative neoplasms ...
12
Leukocytosis at Diagnosis in Patients with Essential Thrombocythemia Is a Risk Factor for Transformation into Myelofibrosis
... Recently, the different prognosis of ET and early/pre- fibrotic PMF has been underlined and some risk factors included high leukocyte count have been proposed as markers of occult early/prefibrotic PMF explaining their ...
5
Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.
... the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), and chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) and acute myeloid leukemia ...
9
Low-dose methotrexate in myeloproliferative neoplasm models
... demonstrated significant hematological and symptomatic improvements in two Italian MPN patients following low-dose MTX treatment. 16 In the light of these results, we suggest that clinical trials should be undertaken to ...
25
IL 33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
... Myeloproliferative neoplasms (MPNs) are characterized by the clonal expansion of one or more myeloid cell lineage. In most cases, proliferation of the malignant clone is ascribed to defined genetic alterations. ...
14